Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

March 31, 2008

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

oxaliplatin, gemcitabine, bevacizumab

"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90\* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.~Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:~Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"

Trial Locations (1)

33140

Mount Sinai Medical Center, Miami Beach

Sponsors
All Listed Sponsors
collaborator

Sanofi-Synthelabo

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Mt. Sinai Medical Center, Miami

OTHER